RecruitingNCT05882773
Asian Myeloproliferative Neoplasm (MPN) Registry
Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.
Sponsor
The University of Hong Kong
Enrollment
1,000 participants
Start Date
May 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.
Eligibility
Min Age: 18 Years
Inclusion Criteria10
- Age ≥ 18 years old at the time of diagnosis of MPN.
- Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):
- Polycythaemia vera
- Essential thrombocythemia
- Primary myelofibrosis, pre-fibrotic/early stage
- Primary myelofibrosis, overt fibrotic stage
- Post-polycythaemia vera myelofibrosis
- Post-essential thrombocythaemia myelofibrosis
- MPN-unclassifiable
- All subjects need to provide informed consent.
Exclusion Criteria2
- A subject will not be eligible if he/she meets any of the following criteria:
- \. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05882773
Related Trials
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
NCT061385872 locations
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
NCT040247612 locations
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879163 locations
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346171 locations
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT044931641 location